Infinitopes Revolutionizing Cancer Treatment with £12.8M Seed Financing

Infinitopes Precision Immunomics, a UK-based cancer biotech company, secures £12.8M in seed funding to accelerate the development of precision cancer vaccines targeting multiple solid tumor indications. Led by CEO Jonathan Kwok, Infinitopes combines cutting-edge antigen discovery technologies with innovative vaccine delivery systems to transform cancer care. The funding round, led by Octopus Ventures, paves the way for the start of phase I/IIa trials for their lead vaccine candidate, ITOP1, in Q3 2024. Infinitopes' unique approach aims to revolutionize cancer treatment by selecting the right targets, with the right vectors, for the right patients, at the right time in their treatment journey. The company's rapid progress and growth have garnered support from key investors and industry experts, positioning them as a leader in the fight against cancer. Visit www.infinitopes.com for more information.